CoChat
Sign Up
Cited by 180Liver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and ProtectionLiver physiology and pathology

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease

Open access
Simon, Tracey G., Henson, Jacqueline, Osganian, Stephanie, Masia, Ricard, Chan, Andrew T., Chung, Raymond T., Corey, Kathleen E.·2019·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2019.04.061PMC PMC6842070
Open this paper in CoChat — free account

Abstract

Background & aims There are few data from prospective studies on the effects of aspirin on fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).Methods We performed a prospective cohort study of 361 adults with biopsy-confirmed NAFLD, from 2006 through 2015, examined every 3-12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase to platelet ratio indices). Histologic analyses of liver biopsies collected at baseline were performed by a blinded pathologist. Information collected at baseline and at each examination included frequency and duration of aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. Using multivariable-adjusted logistic regression, we estimated the association of aspirin use with prevalent steatohepatitis (NASH) and fibrosis. Using multivariable-adjusted Cox proportional hazards modeling, we estimated the association between aspirin use and risk for fibrosis progression.Results At enrollment, 151 subjects used aspirin daily. Compared with non-regular use, daily aspirin use was associated with significantly lower odds of NASH (adjusted odds ratio, 0.68; 95% CI, 0.37-0.89) and fibrosis (adjusted odds ratio, 0.54; 95% CI, 0.31-0.82). Among individuals with baseline F0-F2 fibrosis (n = 317), 86 developed advanced fibrosis over 3692 person-years. Daily aspirin users had significantly lower risk for developing incident advanced fibrosis vs non-regular users (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.43-0.85). This relationship appeared to be duration dependent (adjusted P trend=.026), with the greatest benefit found with at least 4 years or more of aspirin use (aHR, 0.50; 95% CI, 0.35-0.73). Conversely, use of nonaspirin NSAIDs was not associated with risk for advanced fibrosis (aHR, 0.93; 95% CI, 0.81-1.05).Conclusions In a prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and lower risk for progression to advanced fibrosis with time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2019.04.061

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 4

  1. Brunt, 2011, Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings, Hepatology, 53, 810, 10.1002/hep.24127 · DOI · Paper page
  2. Sterling, 2006, Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, 43, 1317, 10.1002/hep.21178 · DOI · Paper page
  3. Lin, 2011, Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis, Hepatology, 53, 726, 10.1002/hep.24105 · DOI
  4. Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 · DOI

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E.
Affiliations
  • Harvard University (US)
  • Brigham and Women's Hospital (US)
  • Massachusetts General Hospital (US)
  • Broad Institute (US)
Corresponding author
Corey, Kathleen E.
ORCID
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2019-12
Volume
17
Issue
13
Pages
2776-2784.e4
ISSN
1542-3565 (ISSN-L)
DOI
10.1016/j.cgh.2019.04.061
PMC
PMC6842070
OpenAlex
W2944339954
Cited by
180
References
36
Citations by year
2026: 10 · 2025: 28 · 2024: 30 · 2023: 25 · 2022: 27 · 2021: 30 · 2020: 20 · 2019: 10
FWCI
16.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Gastroenterology and Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • NIH (K24DK078772, K23DK122104, K23DK099422, K24DK098311, R01 CA137178, 5P30DK046200-25)
  • NCI
  • AASLD
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
aspirin, non-alcoholic fatty liver disease, liver fibrosis progression, nonalcoholic steatohepatitis, nonsteroidal anti-inflammatory drugs, NSAID use, FIB-4, NAFLD fibrosis score, aspartate aminotransferase to platelet ratio index
MeSH terms
Duration of Therapy, Adult, Aged, Aspartate Aminotransferases, Aspirin, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Platelet Aggregation Inhibitors, Platelet Count, Prospective Studies, Cohort Studies, Multivariate Analysis, Logistic Models, Proportional Hazards Models, Disease Progression, Non-alcoholic Fatty Liver Disease, Protective Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review